June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Effects of Intravitreal Faricimab 6.0 mg Injection on Functional and Anatomic Outcomes in Patients with Neovascular Age-related Macular Degeneration.
Author Affiliations & Notes
  • Saagar Pandit
    Retina, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Taku Wakabayashi
    Retina, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Hana Mansour
    Retina, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Bahram Pashaee
    Population Health, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
  • Allen Chiang
    Retina, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Jason Hsu
    Retina, Wills Eye Hospital, Philadelphia, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Saagar Pandit None; Taku Wakabayashi None; Hana Mansour None; Bahram Pashaee None; Allen Chiang None; Jason Hsu None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2235. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Saagar Pandit, Taku Wakabayashi, Hana Mansour, Bahram Pashaee, Allen Chiang, Jason Hsu; Effects of Intravitreal Faricimab 6.0 mg Injection on Functional and Anatomic Outcomes in Patients with Neovascular Age-related Macular Degeneration.. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2235.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To elucidate the effects of intravitreal faricimab 6.0 mg on functional and anatomic outcomes in previously treated patients with neovascular age-related macular degeneration (nAMD).

Methods : Retrospective chart review was performed on nAMD patients previously treated with intravitreal bevacizumab, ranibizumab, and/or aflibercept who received ≥1 injection of intravitreal faricimab 6.0 mg. Exclusion criteria included patients with secondary causes of choroidal neovascularization such as myopic degeneration, polypoidal choroid vasculopathy, trauma, and idiopathic. Fibrovascular pigment epithelial detachment (fvPED) height was measured by two independent graders using the foveal horizontal raster on OCT capturing the maximum height of the fvPED from Bruch’s membrane to the outer margin of the hyperreflective RPE layer. Central foveal thickness (CFT) was measured from the internal limiting membrane (ILM) to Bruch’s membrane. Image J software was used to analyze OCT images. Paired t-tests were used to compare the mean logarithm of minimum angle of resolution visual acuity (logMAR VA), fvPED height (µ) and CFT (µ) at the baseline visit at which the first faricimab injection was given and at the final visit after receiving the last faricimab intravitreal injection(s).

Results : 240 patients met inclusion criteria. Preliminary analyses of 32 eyes of 31 patients were performed. Median age was 83.5 years, 58% (18/31) were female, and 90% (28/31) were pseudophakic. The median number of intravitreal injections received prior to the first faricimab 6.0 mg injection was 48.5 (mean 53 ± 34). The median number of faricimab 6.0 mg injectons received was 3 (mean 3.2 ±1.4). Mean logMAR VA at baseline was 0.74±0.67 (~20/110), and final mean logMAR VA was 0.70±0.68 (~20/100) [p = 0.53]. Mean fvPED height was 181 μ at baseline which decreased to 162 μ at the final visit (p=0.002). Mean CFT was 379 μ at baseline and 357 μ at the final visit (p=0.20).

Conclusions : A statistically significant decrease in fvPED height was found after at least one intravitreal faricimab 6.0 mg injection in patients with previously treated nAMD. Further data analysis is required to verify these results.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×